The overarching goal of the Wake Forest NCORP Cancer Center Research Base (WF NCORP RB) is to improve patient well-being and the quality of cancer care by developing, implementing and successfully completing innovative and feasible Cancer Control and Cancer Care Delivery (CCDR) clinical research studies. For nearly two decades as a CCOP and now NCORP Research Base, Wake Forest has maintained an exclusive focus on Cancer Control and CCDR studies and has emphasized efficient operational processes and extensive interactions with our NCORP Community Site and Minority Underserved Community Site partners. During the first 4 years of the NCORP network, the WF NCORP RB: opened 7 Cancer Control and 3 CCDR studies; enrolled 1,140 participants on WF NCORP RB studies; obtained approval for 5 additional concepts and protocols bringing the total remaining and planned accrual for active and pending trials to over 4,420 participants; and achieved a 33% accrual rate of racial/ethnic minority participants, as well as 68% women, 14% rural residents and 26% age 65 or greater. Over the next 6 years, we will build on and strengthen this highly successful platform by accomplishing the following Specific Aims:
Specific Aim 1 : Extend our cancer control clinical research activities in the following areas: cardiovascular complications of cancer therapy; radiation and chemotherapy-induced neurocognitive toxicities; and additional cancer and treatment-related symptoms and related-outcomes prioritized by NCI steering committees and those commonly associated with novel emerging treatment paradigms.
Specific Aim 2 : Elucidate and intervene upon patient, family, clinician, and organizational factors that influence cancer care delivery, emphasizing survivorship care, informal cancer caregivers and implementation of evidence-based supportive care services.
Specific Aim 3 : Illuminate biological mechanisms underlying cancer and treatment-related symptoms and toxicities in new and innovative multidisciplinary collaborative studies taking advantage of our growing biobank of blood, urine and salivary fluid specimens.
Specific Aim 4 : Identify and address determinants of cancer disparities via disparities-focused studies, integrated aims focused on underserved populations, and targeted recruitment of racial and ethnic minority and underserved populations across all Wake Forest NCORP research investigations.
Specific Aim 5 : Train the next generation of Cancer Control and CCDR researchers through mentoring and involvement of early career faculty, oncology trainees, post-doctoral fellows, and students in WF NCORP activities. Our ongoing and proposed Cancer Control and CCDR studies will continue to improve oncology care by informing best practices for symptom and late effect management as well as efficient, patient-centered, evidence-based cancer care delivery for diverse patient populations. In the next funding period, the WF NCORP RB will help accelerate the translation of knowledge in cancer control and cancer care delivery through close partnership with community and minority underserved sites and studies designed for future dissemination and implementation.

Public Health Relevance

The Wake Forest NCORP Research Base develops and implements multi-site Cancer Control and Cancer Care Delivery (CCDR) clinical research studies in partnership with NCORP Community and Minority/Underserved Community Sites to improve patient well-being and the quality of cancer care.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
2UG1CA189824-06
Application #
9771993
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Russo, Sandra
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2019-08-20
Budget End
2020-07-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
Wake Forest University Health Sciences
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
937727907
City
Winston-Salem
State
NC
Country
United States
Zip Code
27157
Cathcart-Rake, Elizabeth J; Zemla, Tyler; Jatoi, Aminah et al. (2018) Acquisition of sexual orientation and gender identity data among NCI Community Oncology Research Program practice groups. Cancer :
Lamar, Zanetta S; Dothard, Andrew; Kennedy, LeAnne et al. (2018) Hyperglycemia during first-line R-CHOP or dose adjusted R-EPOCH chemotherapy for non-Hodgkin lymphoma is prevalent and associated with chemotherapy alteration - a retrospective study. Leuk Lymphoma 59:1871-1877
Datta, Mridul; Shaw, Edward G; Lesser, Glenn J et al. (2018) A Randomized Double-Blind Placebo-Controlled Trial of Fruit and Vegetable Concentrates on Intermediate Biomarkers in Head and Neck Cancer. Integr Cancer Ther 17:115-123
Carlos, Ruth C; Sicks, JoRean D; Chang, George J et al. (2017) Capacity for Cancer Care Delivery Research in National Cancer Institute Community Oncology Research Program Community Practices: Availability of Radiology and Primary Care Research Partners. J Am Coll Radiol 14:1530-1537
Okoukoni, Catherine; McTyre, Emory R; Ayala Peacock, Diandra N et al. (2017) Hippocampal dose volume histogram predicts Hopkins Verbal Learning Test scores after brain irradiation. Adv Radiat Oncol 2:624-629
Gifford, Abigail R; Lawrence, Julia A; Baker, Laura D et al. (2017) National Institute on Aging /Alzheimer's Association criteria for Mild Cognitive Impairment applied to chemotherapy treated breast cancer survivors. J Oncol Research 1:
Jordan, Jennifer H; Vasu, Sujethra; Morgan, Timothy M et al. (2016) Anthracycline-Associated T1 Mapping Characteristics Are Elevated Independent of the Presence of Cardiovascular Comorbidities in Cancer Survivors. Circ Cardiovasc Imaging 9:
Lawrence, J A; Griffin, L; Balcueva, E P et al. (2016) A study of donepezil in female breast cancer survivors with self-reported cognitive dysfunction 1 to 5 years following adjuvant chemotherapy. J Cancer Surviv 10:176-84
Danhauer, Suzanne C; Griffin, Leah P; Avis, Nancy E et al. (2015) Feasibility of implementing a community-based randomized trial of yoga for women undergoing chemotherapy for breast cancer. J Community Support Oncol 13:139-147
Greven, Kathryn M; Case, L Douglas; Nycum, Lawrence R et al. (2015) Effect of ArginMax on sexual functioning and quality of life among female cancer survivors: results of the WFU CCOP Research Base Protocol 97106. J Community Support Oncol 13:87-94

Showing the most recent 10 out of 13 publications